Glioblastoma Multiforme — Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age
Citation(s)
Phase I/II Trial of Repeat Dosing of Super-Selective Intraarterial Infusion of Erbitux (Cetuximab) and Avastin (Bevacizumab) for Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age